Search for Multi-Stage Mutation Resistant HIV Drug: A DFT Study

Author(s):  
Arijit Bag

Recent advances of computational methodology to predict the important properties of a drug, like IC50, LogP, CC50, etc., assist in model and in-silico characterization of these compounds as a drug for variant deadly diseases. With the help of these methodologies, the drug potency of thio-propionate derivatives of iron, ruthenium and osmium carbonyl clusters which are less toxic, water soluble and easy metabolic, are tested as HIV drug along with their metabolic probability study. It is observed that IC50 of Ru5(CO)14(m -H)(m -S(CH2)2COO-)Na+ is only 220 picomole as HIV-1 capsid A inhibitor. Its inhibition activities in other enzymatic processes involved in the HIV life cycle in the human body are also studied and compared with the most used market available drugs. It is observed that this modeled compound shows excellent inhibition activities at different stages of HIV life-span inside the human body and could be considered as a multi-stage, mutation resistant HIV drug.<br>

2020 ◽  
Author(s):  
Arijit Bag

Recent advances of computational methodology to predict the important properties of a drug, like IC50, LogP, CC50, etc., assist in model and in-silico characterization of these compounds as a drug for variant deadly diseases. With the help of these methodologies, the drug potency of thio-propionate derivatives of iron, ruthenium and osmium carbonyl clusters which are less toxic, water soluble and easy metabolic, are tested as HIV drug along with their metabolic probability study. It is observed that IC50 of Ru5(CO)14(m -H)(m -S(CH2)2COO-)Na+ is only 220 picomole as HIV-1 capsid A inhibitor. Its inhibition activities in other enzymatic processes involved in the HIV life cycle in the human body are also studied and compared with the most used market available drugs. It is observed that this modeled compound shows excellent inhibition activities at different stages of HIV life-span inside the human body and could be considered as a multi-stage, mutation resistant HIV drug.<br>


1991 ◽  
Vol 30 (25) ◽  
pp. 4732-4739 ◽  
Author(s):  
Thomas H. Walter ◽  
Greg R. Frauenhoff ◽  
John R. Shapley ◽  
Eric. Oldfield

1985 ◽  
Vol 131 (3-4) ◽  
pp. 363-369 ◽  
Author(s):  
R. Zanoni ◽  
V. Carinci ◽  
Raja H. Abu-Samn ◽  
R. Psaro ◽  
C. Dossi

1994 ◽  
Vol 5 (6) ◽  
pp. 387-394 ◽  
Author(s):  
H. Schott ◽  
M. P. Häussler ◽  
P. Gowland ◽  
D. H. Horber ◽  
R. A. Schwendener

N4-hexadecyl-5′-0-(4-monomethoxytrityl)-2′-deoxycytidine-3′-hydrogenphosphate was reacted with 3′-azido-2′,3′-dideoxythymidine (AZT) according to the hydrogenphosphate method to yield N4-hexadecyl-2′-deoxycytidylyl-(3′-5)-3′-azido-2′,3′-dideoxythymidine. N4-palmitoyl-5′-O-(4-monomethoxytrityl)-2′-deoxycytidine-3′-(2-chlorophenyl)-phosphate was condensed to AZT using the triester method to give N4-palmitoyl-2′-deoxycytidylyl-(3′-5′)-3,-azido-2′,3′-dideoxythymidine. Both dinucleosidephosphates have amphiphilic properties and represent a new class of AZT derivatives in which the polar AZT-5′-monophosphate is masked with lipophilic deoxycytidine residues of variable stability. The AZT derivatives are water soluble, by forming micelles, and as a result of their amphiphilic nature, they can be incorporated into the lipid membranes of liposomes. In contrast to the micellar drug preparations, the liposomal formulations were shown to exert no lytic activity on human erythrocytes. Both AZT derivatives have anti HIV-1 activity in vitro.


Author(s):  
Telisha Traut ◽  
Raymond Hewer ◽  
Judy Coates ◽  
D. Bradley G. Williams

Screening of an HIV-1 IN model against database-derived chemical structures identified pyrrole-carbaldehydes as targets for further development. Chemical synthesis using a facile one-pot reaction resulted in the generation of a compound library. Preliminary toxicity and efficacy assays of the water-soluble HCl-salt derivatives of each compound support the in silico predictions.


Sign in / Sign up

Export Citation Format

Share Document